Skip to content

Price / book at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
1.9×-0.8×
IAR
Integra LifeSciencesIART
0.7×-0.4×
Solventum logo
SolventumSOLV
2.3×-1.8×
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
1.1×-0.3×
ClearPoint Neuro logo
ClearPoint NeuroCLPT
14.3×-2.1×
Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
1.6×+0.1×

Other financials

Income statement

See full
Revenue$27.8M+18.6%
Gross profit$25.9M+19.8%
Operating income$2.6M+221%
Net income$459.0K+113%
EPS (diluted)$0.05+112%

Balance sheet

See full
Cash & equivalents$13.6M-34.3%
Total debt$48.4M+8.2%
Total equity$7.0M-80.8%
Total assets$69.3M-28.1%

Cash flow

See full
Operating cash flow-$2.5M-23.3%
CapEx$43.8K-97.5%
Free cash flow-$2.5M+32.6%

Valuation

See full
Market cap$216.18M-9.7%
Enterprise value$250.95M-6.5%
P/S-0.5×

Profitability

See full
Gross margin92.9%+1.8pp
Operating margin6.1%+5.1pp
Net margin-31.2%-93.4pp
FCF margin-9.8%-3.5pp

Returns & leverage

See full
Return on equity-153.7%-199pp
Debt / equity6.9×+5.7×
Current ratio2.3×-0.5×

Where this comes from

Calculated from Sanara MedTech Inc.’s reported figures.

Based on the most recent quarter.

The official record: Sanara MedTech Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sanara MedTech Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sanara MedTech Inc.'s price / book?
Sanara MedTech Inc. (SMTI) reported price / book of 22.4× in Q1 2026.
How has Sanara MedTech Inc.'s price / book changed year-over-year?
Sanara MedTech Inc.'s price / book increased by 199.0% year-over-year, from 7.5× to 22.4×.
What is the long-term trend for Sanara MedTech Inc.'s price / book?
Over 5 years (2020 to 2025), Sanara MedTech Inc.'s price / book has grown at a -8.7% compound annual growth rate (CAGR), from 55.3× to 35.1×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.